Literature DB >> 3958387

Circulating IgG autoantibodies to IgE in atopic syndromes.

I Quinti, C Brozek, N Wood, R S Geha, D Y Leung.   

Abstract

Sera from nonatopic healthy donors and patients with hyper-IgE syndrome, allergic respiratory disease, i.e., allergic rhinitis and asthma, and atopic dermatitis were assayed for the presence of IgG and IgM antibodies to IgE. The assay used was based on an ELISA method that measured the binding of IgG or IgM in test sera to myeloma IgE (PS)-coated microtiter wells. The levels of IgG anti-IgE but not of IgM anti-IgE were elevated in patient sera of all three categories tested. The same sera failed to demonstrate increased levels of IgG anti-IgM or IgG anti-IgA. Significant IgG anti-IgE activity remained after absorption of patient sera over pooled human IgG F(ab')2 Sepharose. The IgG anti-IgE activity appeared to be directed toward the Fc portion of IgE because absorption of positive sera over IgE (ADZ) Sepharose but not over myeloma IgG Sepharose completely removed their reactivity with IgE (PS) and because sera from atopic individuals but not from normal subjects contained IgG anti-IgE activity against the protein backbone of the Fc portion of IgE synthesized from a fragment of the cloned gene of human myeloma IgE (ND) heavy chain. Regression analysis demonstrated a weak but significant correlation (r = 0.31; p less than 0.05) between serum IgE levels and IgG anti-IgE activity. Fractionation of sera from the three patient categories by gel filtration over Sepharose 6B revealed that IgG anti-IgE activity was present both as monomeric IgG and in IgE containing immune complexes (IC). Intermediate molecular size IC (between 7S and 19S) were present in all three patient groups.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3958387     DOI: 10.1016/0091-6749(86)90350-7

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  11 in total

1.  The high-affinity IgE receptor (FcepsilonRI) blocks apoptosis in normal human monocytes.

Authors:  N Katoh; S Kraft; J H Wessendorf; T Bieber
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

Review 2.  Immunopathology of atopic dermatitis.

Authors:  D Y Leung
Journal:  Springer Semin Immunopathol       Date:  1992

Review 3.  Clinical significance of anti-IgE autoantibodies and immune complexes containing IgE.

Authors:  C G Magnusson; S G Johansson
Journal:  Clin Rev Allergy       Date:  1989

4.  Do IgE-IgG complexes occur in the circulation?

Authors:  L Boluda; L Berrens
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

5.  Induction of high titers of anti-IgE by immunization of inbred mice with syngeneic IgE.

Authors:  S Haba; A Nisonoff
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

6.  Serum IgG autoantibodies directed against the alpha chain of Fc epsilon RI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients?

Authors:  E Fiebiger; D Maurer; H Holub; B Reininger; G Hartmann; M Woisetschläger; J P Kinet; G Stingl
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

7.  Autoantibodies to IgE can induce the release of proinflammatory and vasoactive mediators from human cardiac mast cells.

Authors:  Remo Poto; Vincenzo Patella; Gjada Criscuolo; Gianni Marone; Enrico Coscioni; Gilda Varricchi
Journal:  Clin Exp Med       Date:  2022-07-25       Impact factor: 5.057

8.  Induction of an auto-anti-IgE response in rats. IV. Effects on mast cell degranulation.

Authors:  G Jaffery; E B Bell; J W Coleman
Journal:  Immunology       Date:  1993-04       Impact factor: 7.397

Review 9.  Autoimmune urticaria.

Authors:  Malcolm Greaves
Journal:  Clin Rev Allergy Immunol       Date:  2002-10       Impact factor: 8.667

10.  Selective deficiency of interferon-gamma production in the hyper-IgE syndrome. Relationship to in vitro IgE synthesis.

Authors:  R Paganelli; E Scala; M R Capobianchi; E Fanales-Belasio; G D'Offizi; M Fiorilli; F Aiuti
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.